Latest from Moffitt

Kenneth H. Shain, MD, PhD, assistant member, Moffitt Cancer Center, discusses emerging agents in multiple myeloma.
Jonathan R. Strosberg, MD, associate professor, Moffitt Cancer Center, shares his insight on the current field of neuroendocrine tumors (NETs).
Bijal D. Shah, MD, medical oncology, of Moffit Cancer Center, discusses the status of chimeric antigen receptor (CAR) T-cell therapy in acute lymphoblastic leukemia (ALL).
Rachid Baz, MD, hematologist and medical oncologist, Moffitt Cancer Center, discusses how treatment approaches vary for patients with multiple myeloma.
Jonathan Strosberg, MD, medical oncologist, Department of Gastrointestinal Oncology, section head, Neuroendocrine Division, chair, Gastrointestinal Department Research Program, Moffitt Cancer Center, discusses trials in neuroendocrine tumors (NETs).
Jonathan R. Strosberg, MD, associate professor, Moffitt Cancer Center, discusses the challenges associated with treating neuroendocrine tumors (NETs).
Results of a phase II trial showed that more than 80% of patients with refractory non-Hodgkin lymphoma achieved objective responses to treatment with the chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel.
John E. Mullinax, MD, discusses isolated limb infusion as a limb salvage strategy for locally advanced extremity sarcoma.
Publication Bottom Border
Border Publication